MERZ-AESTHETICS
5.11.2020 09:32:12 CET | Business Wire | Press release
Merz Aesthetics, a global leader in medical aesthetics, today announced the presentation of data from its medical aesthetics portfolio at the 18th edition of the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place virtually as “AMWC Global 2020, The Virtual Edition”, to be held from Thursday, November 5 to Saturday, November 7, 2020. Merz Aesthetics is an elite sponsor of the global industry congress.
“We are proud to continue our commitment to the medical aesthetics industry by sponsoring this virtual meeting. We are looking forward to sharing data on the Merz Aesthetics portfolio, engage with our customers and partners and present Merz Aesthetics in a new innovative format. It’s time to think differently to keep the momentum of the industry,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics.
In addition to the presentations listed below, Merz Aesthetics is sponsoring two symposium events to be held over the course of the meeting and led by renowned medical aesthetic experts:
“The Skin You Are In – Collagen Expert Session” to be held on Friday, November 6, 15:15h – 16:15h CET. The session will include injection videos and insights from renowned international experts:
- Dr. Gabriela Casabona – Aesthetic Physician, Spain
- Dr. Jani van Loghem – Aesthetic Physician, The Netherlands
- Professor Yana A. Yutskovskaya – Dermatologist, Russia
“conFRONT every LINE! – Upper Face Rejuvenation” to be held on Saturday, November 7, 12:30h – 13:30h CET. The session will include injection videos and insights from renowned international experts:
- Dr. Tatjana Pavicic – Dermatologist, Germany
- Dr. Thomas Rappl – Dermatologist, Austria
Oral Presentations
Gabriela Casabona: ‘CaHA as a Biostimulator’ (Evolution of Regenerative Aesthetics Where are We Now Session); Thursday, November 5, 13:30-15:30h CET, AMWC Stream 2*
Dr. Carla Pecora: ‘Botulinum Toxin Injection: Customized Eyebrow Reshape and Positioning, with an Individualized Approach’ (Forehead Treatment and Importance of the Eyebrow Line Session); Thursday, November 5, 16:30-18:30h CET, AMWC Stream 1*
Dr. Daria Voropai: ‘Midface Dilemmas: How Individual Approaches Require a Multiple Tissue Plane Approach and How Ultrasound, Tactile Feedback, Visual Cues Help Us to Achieve This’ (Cheeks: Fillers, Threads of Both? Session); Friday, November 6, 16:30-18:30h CET, AMWC Stream 2 *
Dr. Kate Goldie: ‘Redefining the Art of the Lip’ (Lips and Perioral Rejuvenation Session); Saturday, November 7th, 14:00-16:00h CET, AMWC Stream 2 *
Virtual E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress.
Botulinum Toxin
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. Martina Kerscher, MD - Germany, Sabrina Fabi, MD – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, Dr. med – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
- Decreased Therapeutic Effect Over Time Amongst Botulinum Toxin Type A Agents. Rashid Kazerooni – Merz North America, USA.
- Neurotoxin Impurities: A Review of Threats to Efficacy. Je-Young Park, MD - USA, Owen Sunga, MD, MSc – Singapore, Rungsima Wanitphakdeedecha, MD, MA, MSc – Thailand, Jürgen Frevert, PhD - Germany.
Belotero®
- Safety of Cohesive Polydensified Matrix Cross-Linked Hyaluronic Acid Volumizing Gel in Temporal Hollows and Cheeks: A Prospective, Open-Label, Post-Market Study. Tatjana Pavicic, MD –Germany; Gerhard Sattler, MD – Germany, Welf Prager, MD – Germany, Tanja Fischer, MD PhD – Germany, Gerd Gauglitz, MD – Germany, Matthias Hofmann, PhD - Germany; Hanna Dersch – Germany; Shahbaz Riaz, PharmD – USA, Martina Kerscher, MD – Germany.
- Hydration Effect of a Revitalizing CPM® Cross-Linked Hyaluronic Acid Gel Containing Glycerol. Kay Marquardt, Sabine Falk, Matthias Hofmann, Jeannette Simon, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
Radiesse®
- CaHA microspheres remodel collagen networks leading to improved skin quality and reveal new treatment possibilities. Gabriela Casabona, MD – Spain, Bartosch Nowag, Daniela Schäfer, Davide Greco, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany
- Combination of Calcium Hydroxylapatite Diluted with Normal Saline and Microfocused Ultrasound with Visualization for Skin Tightening. Yana Alexandrovna Yutskovskaya, MD - Russia, Anna Daniilovna Sergeeva, MD – Russia, Evgeniya Altarovna Kogan, MD PhD – Russia.*
Ultherapy®
- Optimizing Patient Outcomes through a Customized Approach of Microfocused Ultrasound with Visualization Treatments: Consensus Guidelines from an Expert Panel. Sabrina G. Fabi, MD - USA, John Joseph, MD - USA, Julia Sevi, MD PhD - UK, Jeremy B. Green, MD - USA, Jennifer Deaver Peterson, MD – USA.
*Merz-supported Investigator Initiated Trial
About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom